The next generation TIL therapy company 



Collaboration Partners

About Cbio

Cbio A/S is a clinical stage biopharmaceutical company dedicated to curing cancer patients by making T-cell based immunotherapies available for patients worldwide. We focus on the so-called Tumor Infiltrating Lymphocyte – or TIL therapy, which is the most promising cell-based treatment for solid tumors.  


Cbio’s mission is to develop and bring next-generation cell-based immunotherapies to cancer patients worldwide.

Pursuing our mission, we are developing next generation TIL therapies for solid tumors, accounting for 90% of all cancers. Our transformative new TIL product – novoleucel – enables more patients to be treated due to its minimal invasiveness, a broader T-cell repertoire, its short production time and industrial scalability without compromising yield.



Cbio is located in Søborg, Copenhagen, in a 1,000 m2 state-of-the-art facility holding a manufacturing authorization to produce cell-based Advanced Therapy Medicinal Products (ATMPs) for clinical use. The facility is hosting the Company’s research, development and manufacturing activities and has cleanroom facilities with a current capacity to produce TIL products for up to 150 patients per year. Cbio is planning to further expand the cleanroom infrastructure in order to increase the capacity to up to 600 TIL patients per year. 

Collaboration Partners

Herlev Hospital

Cbio has licensed the clinically proven TIL product ‘novoleucel’ from the world-leading academic institution, Herlev Hospital in Denmark. Herlev has since 2009 pioneered TIL clinical trials in Europe and has demonstrated remarkable clinical results with their high-dose TIL product in late-stage, heavily pre-treated cancer patients where all other treatment alternatives have been exhausted. More than 100 patients have been treated with TILs in 9 clinical trials targeting 12 different solid tumor indications, including metastatic melanoma, cervical, head & neck and non-small cell lung cancers. Together with Netherlands’ Cancer Institute, Herlev is currently running a phase III clinical study in metastatic melanoma.

University of Copenhagen

Cbio has established a 3-year research collaboration with Krister Wennerberg’s group at the Biotech Research and Innovation Centre, University of Copenhagen (BRIC). The aim of the project is to improve the TIL therapy product, make the production process more scalable and potentially further improve Cbio’s proprietary TIL stimulator cocktail using high-throughput screening facilities at BRIC. The project is supported by the Innovation Fund Denmark through the industry PhD program.

Odense University Hospital

Cbio is collaborating with Odense University Hospital with the aim to develop and pre-clinically optimize TIL products for colorectal, kidney, ovarian and pancreatic cancer patients. The collaboration entails 4 clinical departments as well as the Pathological Institute and is approved by the Ethical Committee from Region South Denmark. By combining Cbio’s unique knowhow on TIL stimulators and ways to also generate successful TIL products from less immunogenic tumors with Odense’s pathologist expertise, the aim is to develop TIL products for these four cancer indications that could be tested clinically at a later stage.